Myovant Sciences Ltd. (MYOV)
NYSE: MYOV
· Real-Time Price · USD
26.98
-0.01 (-0.04%)
At close: Mar 09, 2023, 10:01 PM
Myovant Sciences Revenue Breakdown
| Period Ending | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
|---|---|---|---|---|---|---|---|
| Amortization of Regulatory Milestone Revenue | 8.33M | 33.6M | 4.17M | 778K | 4.2M | 4.2M | 8.54M |
| Amortization of Regulatory Milestone Revenue Growth | -75.20% | +706.41% | +435.60% | -81.47% | 0.00% | -50.81% | n/a |
| Amortization of Upfront Payment Revenue | 20.97M | 20.97M | 20.97M | n/a | 20.97M | 20.97M | 20.97M |
| Amortization of Upfront Payment Revenue Growth | 0.00% | 0.00% | n/a | -100.00% | 0.00% | 0.00% | n/a |
| ORGOVYX Revenue | 48.72M | 300K | 25.14M | 2.22M | 2.45M | 31.67M | n/a |
| ORGOVYX Revenue Growth | +16141.33% | -98.81% | +1031.46% | -9.16% | -92.28% | n/a | n/a |
| License and Service Revenue | 4M | n/a | 1.32M | 29.42M | n/a | 629K | 1.07M |
| License and Service Revenue Growth | n/a | -100.00% | -95.52% | n/a | -100.00% | -41.49% | n/a |
| License Revenue | 5M | 6.4M | 50M | 32.42M | 2.43M | 18.66M | 10.48M |
| License Revenue Growth | -21.91% | -87.19% | +54.21% | +1234.87% | -86.98% | +78.10% | n/a |
| MYFEMBREE Revenue | 10.53M | 43.32M | 4M | n/a | 24.39M | 21.06M | 11.55M |
| MYFEMBREE Revenue Growth | -75.70% | +983.25% | n/a | n/a | +15.81% | +82.30% | n/a |
| Product and Service, Other Revenue | 500K | 49.95M | 36.03M | n/a | 29.27M | n/a | n/a |
| Product and Service, Other Revenue Growth | -99.00% | +38.61% | n/a | n/a | n/a | n/a | n/a |
| Product Revenue | 61.42M | 225K | 41.35M | n/a | n/a | n/a | n/a |
| Product Revenue Growth | +27198.67% | -99.46% | n/a | n/a | n/a | n/a | n/a |
| Richter Product Supply and Royalties Revenue | 1.78M | 54.58M | n/a | n/a | n/a | n/a | n/a |
| Richter Product Supply and Royalties Revenue Growth | -96.73% | n/a | n/a | n/a | n/a | n/a | n/a |
| Collaboration Revenue Revenue | 29.31M | n/a | n/a | n/a | n/a | n/a | n/a |
| Collaboration Revenue Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 86.38M | 84.26M | 79.03M | 67.25M | 72.13M | 58.78M | 61.21M | 78.04M | 49.24M | 31.32M | 22.83M | 22.43M | 29.14M | 16.6M | 14.15M | 12.48M | 10.69M | 10.31M | 8.74M | 7.27M | 6.64M | 6.14M | 4.18M | 3.93M | 2.9M | 2.97M | 2.56M |
| Selling, General, and Administrative Revenue Growth | +2.52% | +6.61% | +17.53% | -6.76% | +22.70% | -3.97% | -21.56% | +58.47% | +57.25% | +37.18% | +1.77% | -23.03% | +75.52% | +17.32% | +13.39% | +16.80% | +3.65% | +17.94% | +20.28% | +9.46% | +8.13% | +46.84% | +6.41% | +35.61% | -2.33% | +15.81% | n/a |
| Research and Development Revenue | 31.52M | 26.92M | 23.89M | 24.52M | 25.73M | 26.28M | 30.88M | 21.55M | 30.45M | 40.52M | 44.19M | 41.71M | 48.93M | 50.8M | 51.12M | 59.02M | 58.43M | 53.81M | 51.34M | 40.08M | 34.88M | 24.17M | 17.71M | 19.02M | 6.16M | 3.75M | 14.57M |
| Research and Development Revenue Growth | +17.10% | +12.67% | -2.56% | -4.70% | -2.11% | -14.90% | +43.27% | -29.23% | -24.85% | -8.29% | +5.93% | -14.74% | -3.69% | -0.61% | -13.39% | +1.00% | +8.59% | +4.81% | +28.10% | +14.92% | +44.29% | +36.49% | -6.88% | +208.80% | +64.08% | -74.25% | n/a |